AMENDMENTS TO THE CLAIMS

Please amend the claims as follows:

LISTING OF CLAIMS:

1. (Withdrawn) A method of making a nutraceutical composition for the treatment or prevention of diabetes and/or obesity and syndrome X comprising admixing a catechin found in green tea and a PPARγ ligand to form a nutraceutical composition.

2. (Withdrawn) A method according to claim 1 wherein the PPARγ ligand is selected from the group consisting of a full agonist, a partial agonist, a selective PPARγ modulator/agonist, and a PPARγ dual agonist or panagonist.

3. (Withdrawn) A method according to claim 1 wherein the PPARγ ligand is a thiazolidinedione.

4. (Withdrawn) A method according to claim 1 wherein the PPARγ ligand is a natural PPARγ agonist.

5. (Withdrawn) A method according to claim 1 wherein the PPARγ ligand is a PUFA.

6. (Withdrawn) A method according to claim 1 wherein the PPARγ ligand is ligustilide.

7. (Withdrawn) A method according to claim 1 wherein the PPARγ ligand is phytanic acid.

8. (Withdrawn) A method of treating or preventing diabetes and/or obesity and syndrome X comprising consuming a nutraceutical composition comprising a catechin found in green tea during administration of a PPARγ ligand.

9. (Withdrawn) A method according to claim 8 wherein the nutraceutical composition is a food or beverage or a supplement composition for a food or beverage.

10. (Withdrawn) A method according to claim 8 wherein the nutraceutical composition is a pharmaceutical composition.

11. (Withdrawn) A method according to claim 8 wherein the catechin is (-) epigallocatechin gallate.

12. (Withdrawn) A method for the treatment or prevention of diabetes or obesity and syndrome X which comprises administering to a subject in need of such treatment an effective amount of a catechin found in green tea and of a PPARγ ligand.

13. (Withdrawn) The method as in claim 12 wherein the catechin is (-) epigallocatechin gallate.

14. (Cancelled).

15. (Currently amended) ~~A composition as in~~ The solid unit oral dosage form according to claim ~~14~~ 24 wherein the catechin is (-) epigallocatechin gallate.

16. (Withdrawn): A composition according to claim 14, wherein the thiazolidinedione is ciglitazone, rosiglitazone or pioglitazone.

17. (Currently amended): ~~A composition~~ The solid unit oral dosage form according to claim 15 wherein (-) epigallocatechin gallate is present in an amount ~~sufficient to administer to a human adult a daily dosage~~ of about 10 mg to about 2000 mg.

18. (Canceled).

19. (Withdrawn) A method according to claim 3 wherein the thiazolidinedione, is selected from the group consisting of ciglitazone, rosiglitazone and pioglitazone.

20. (Withdrawn) A method according to claim 5 wherein the PUFA is selected from the group consisting of eicosapentaenoic acid and docosahexaenoic acid.

21. (Currently amended) The ~~composition~~ solid unit oral dosage form according to claim ~~14~~ 24 wherein the PPARγ ligand is ligustilide.

22. (Currently amended) The ~~composition~~ solid unit oral dosage form according to claim ~~14~~ 24 wherein the PPARγ ligand is in a dosage of from about 1 to about 1000 mg.

23. (Currently amended) The ~~composition~~ solid unit oral dosage form according to claim ~~14~~ 24 wherein the ~~pharmaceutical composition is a solid unit oral dosage form, the~~ catechin is (-) epigallocatechin gallate and (-) epigallocatechin gallate is present in an amount of from about 10 mg to about 2000 mg, and wherein the PPARγ ligand is present in an amount of from about 1 to about 1000 mg.

24. (Currently amended) ~~The composition according to claim 14 wherein the pharmaceutical composition is a~~ A solid unit oral dosage form for effecting glucose tolerance and ~~preventing~~ inhibiting body weight gain or adipose tissue weight gain associated with use of a PPARγ ligand, comprising a catechin found in green tea, and a peroxisome proliferator-activated receptor gamma (PPARγ) ligand selected from the

group consisting of thiazolidinediones, ligustilide and phytanic acid, wherein ~~and~~ the catechin and the PPARγ ligand are present in glucose lowering amounts.

25. (Cancelled)

26. (Currently amended) A ~~pharmaceutical composition~~ solid unit oral dosage form for effecting glucose tolerance comprising an effective amount of a catechin found in green tea, and of a peroxisome proliferator-activated receptor gamma (PPARγ) ligand selected from the group consisting of thiazolidinediones, ligustilide and phytanic acid, wherein the effective amount of each of the catechin and the PPARγ ligand in combination reduces fasted state glucose concentration and ~~prevents~~ inhibits body weight gain or adipose tissue weight gain associated with use of a PPARγ ligand.

27. (Currently amended) The ~~composition~~ solid unit oral dosage form according to claim 23 wherein the PPARγ ligand is ligustilide.

28. (Cancelled).

29. (Cancelled).

30. (Currently amended) The ~~pharmaceutical composition~~ solid unit oral dosage form according to claim 26 wherein the PPARγ ligand is ligustilide.

31. (Cancelled).

32. (Currently amended) The ~~pharmaceutical composition~~ solid unit oral dosage form according to claim 26 wherein the catechin is (-) epigallocatechin gallate and (-) epigallocatechin gallate is present in an amount of from about 10 mg to about 2000 mg, and wherein the PPARγ ligand is present in an amount of from about 1 to about 1000 mg.

33. (Currently amended) The ~~composition~~ solid unit oral dosage form according to claim 23 wherein the (-)-epigallocatechin gallate is present in an amount of from 100 mg to 300 mg, and the PPARγ ligand is present in an amount of from 8 mg to 100 mg.

34. (Currently amended) The ~~composition~~ solid unit oral dosage form according to claim 23 wherein the (-)-epigallocatechin gallate is present in an amount of about 2000 mg, and the PPARγ ligand is present in an amount of about 1000 mg.